BioPharma

Vistagen’s late-stage CNS pipeline, led by fasedienol™, shows clinical progress and strategic growth despite liquidity pressures and non-material revenue.

Vivos Inc.'s IsoPet® cancer therapy reports record Q1 2025 growth with 150% more treatments, new clinic certifications, and expanded therapeutic applications.

Vivos Inc. reports major progress in its India human trial for RadioGel®, showing high safety and localized tumor treatment precision.

Vivos Inc. Expands IsoPet® Animal Cancer Division in 2025 Vivos Inc. (OTCQB: RDGL) strengthens its IsoPet® division in 2025 with the expansion of clinics, training advancements, and cutting-edge cancer treatments for pets Vivos Inc. (OTCQB: RDGL) continues to make remarkable progress...

Vistagen Therapeutics is making breakthroughs in CNS treatments with PH94B, PH10, and AV-101, offering new hope for anxiety and depression patients.

Vivos Inc. advances cancer treatment with RadioGel® PRnT™ Human trials in India show early success, with Mayo Clinic expansion planned in 2025.